1. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate. (1st July 2015) Authors: Gallant, Joel E.; Koenig, Ellen; Andrade-Villanueva, Jaime F.; Chetchotisakd, Ploenchan; DeJesus, Edwin; Antunes, Francisco; Arastéh, Keikawus; Rizzardini, Giuliano; Fehr, Jan; Liu, Hui C.; Abram, Michael E.; Cao, Huyen; Szwarcberg, Javier Journal: Journal of acquired immune deficiency syndromes Issue: Volume 69:Number 3(2015:Mar.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment. Issue 6 (November 2014) Authors: McDonald, Cheryl K.; Martorell, Claudia; Ramgopal, Moti; Laplante, Francois; Fisher, Martin; Post, Frank A.; Liu, Yapei; Curley, Joanne; Abram, Michael E.; Custodio, Joseph; Graham, Hiba; Rhee, Martin S.; Szwarcberg, Javier Journal: HIV clinical trials Issue: Volume 15:Issue 6(2014) Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment. (1st March 2015) Authors: Post, Frank A.; Winston, Jonathan; Andrade-Villanueva, Jaime F.; Fisher, Martin; Liu, YaPei; Beraud, Christophe; Abram, Michael E.; Graham, Hiba; Rhee, Martin S.; Cheng, Andrew K.; Szwarcberg, Javier Journal: Journal of acquired immune deficiency syndromes Issue: Volume 68:Number 3(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Issue 9 (September 2016) Authors: Squires, Kathleen; Kityo, Cissy; Hodder, Sally; Johnson, Margaret; Voronin, Evgeny; Hagins, Debbie; Avihingsanon, Anchalee; Koenig, Ellen; Jiang, Shuping; White, Kirsten; Cheng, Andrew; Szwarcberg, Javier; Cao, Huyen Journal: Lancet Issue: Volume 3:Issue 9(2016) Page Start: e410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects. (1st July 2016) Authors: Ramanathan, Srini; Custodio, Joseph M.; Wei, Xuelian; Wang, Hui; Fordyce, Marshall; Dave, Ami; Ling, Kah Hiing J.; Szwarcberg, Javier; Kearney, Brian P. Journal: Journal of acquired immune deficiency syndromes Issue: Volume 72:Number 3(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. Issue 3 (4th May 2017) Authors: Arribas, Jose R.; DeJesus, Edwin; van Lunzen, Jan; Zurawski, Christine; Doroana, Manuela; Towner, William; Lazzarin, Adriano; Nelson, Mark; McColl, Damian; Andreatta, Kristen; Swamy, Raji; Szwarcberg, Javier; Nguyen, Thai Journal: HIV clinical trials Issue: Volume 18:Issue 3(2017) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. Issue 4 (4th July 2017) Authors: Pozniak, Anton; Flamm, Jason; Antinori, Andrea; Bloch, Mark; Ward, Douglas; Berenguer, Juan; Cote, Pierre; Andreatta, Kristen; Garner, William; Szwarcberg, Javier; Nguyen-Cleary, Thai; McColl, Damian J.; Piontkowsky, David Journal: HIV clinical trials Issue: Volume 18:Issue 4(2017) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients. Issue 5 (September 2014) Authors: Kulkarni, Rima; Abram, Michael E.; McColl, Damian J.; Barnes, Tiffany; Fordyce, Marshall W.; Szwarcberg, Javier; Cheng, Andrew K.; Miller, Michael D.; White, Kirsten L. Journal: HIV clinical trials Issue: Volume 15:Issue 5(2014) Page Start: 218 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients. Issue 3 (April 2015) Authors: White, Kirsten L; Kulkarni, Rima; McColl, Damian J; Rhee, Martin S; Szwarcberg, Javier; Cheng, Andrew K; Miller, Michael D Journal: Antiviral therapy Issue: Volume 20:Issue 3(2015) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗